Enhancement of Anti-Leukemia Immunity by Leukemia–Derived Exosomes Via Downregulation of TGF-β1 Expression | Zendy

Fang Huang | Zendy; Jiangbo Wan | Zendy; Weiwei Hu | Zendy; Siguo Hao | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Enhancement of Anti-Leukemia Immunity by Leukemia–Derived Exosomes Via Downregulation of TGF-β1 Expression

Author(s) -

Fang Huang,

Jiangbo Wan,

Weiwei Hu,

Siguo Hao

Publication year - 2017

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000484677

Subject(s) - microvesicles , leukemia , cancer research , gene silencing , ctl* , flow cytometry , immunology , exosome , small hairpin rna , downregulation and upregulation , medicine , immune system , biology , microrna , cell culture , gene knockdown , cd8 , biochemistry , genetics , gene

Minimal residual leukemia cells (MRLs) are difficult to eradicate through traditional treatment and therefore remain to be a major threat to the long-term survival of leukemia patients. Tumor-derived exosomes (TEXs), which carry tumor associated antigens (TAA), may be a potential cell-free tumor vaccine for the specific eradication of MRLs. However, TEXs are intended to be less immunogenic due to exosomal TGF-β1. To further optimize the efficacy of TEX-based vaccines, we investigated whether exosomes from TGF-β1 silenced leukemia cells (LEXTGF-β1si) had an increased potential to induce a specific antitumor effect compared with non-modified exosomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research